Abstract
Purpose: This study applied the Clinical Trial Diversity Rating (CDR) Framework to evaluate U.S. asthma trials from the past five years, identifying gaps in representation to improve trial validity and healthcare equity.
Design method: We conducted a systematic review and meta-analysis on U.S. asthma trial diversity using the CDR protocol by Agboola & Wright. Data, extracted and analyzed with the participation-to-disease representation ratio (PDRR), were published on OSF. Representation was categorized as sufficient, underrepresented, or overrepresented, with results shown in forest plots for sex, age, and race/ethnicity.
Results: Our search yielded 1,757 records, with 116 studies ultimately meeting the eligibility criteria after screening. Participant diversity was generally poor: 58.6% of trials were rated 'Poor' for race/ethnicity representation, and only 33.6% received a 'Good' rating for sex. Age data were scarcely reported, with just two trials rated 'Good.' Forest plots revealed significant underrepresentation of Black and Hispanic/Latinx participants in many studies, while white and male participants were often overrepresented.
Discussion: To boost racial diversity in asthma trials, targeted strategies like monetary incentives, community-based recruitment, and mobile health units have been effective. Prioritizing underrepresented groups, such as Puerto Ricans, in future research will ensure trials are more representative, leading to better, more equitable healthcare outcomes.
Design method: We conducted a systematic review and meta-analysis on U.S. asthma trial diversity using the CDR protocol by Agboola & Wright. Data, extracted and analyzed with the participation-to-disease representation ratio (PDRR), were published on OSF. Representation was categorized as sufficient, underrepresented, or overrepresented, with results shown in forest plots for sex, age, and race/ethnicity.
Results: Our search yielded 1,757 records, with 116 studies ultimately meeting the eligibility criteria after screening. Participant diversity was generally poor: 58.6% of trials were rated 'Poor' for race/ethnicity representation, and only 33.6% received a 'Good' rating for sex. Age data were scarcely reported, with just two trials rated 'Good.' Forest plots revealed significant underrepresentation of Black and Hispanic/Latinx participants in many studies, while white and male participants were often overrepresented.
Discussion: To boost racial diversity in asthma trials, targeted strategies like monetary incentives, community-based recruitment, and mobile health units have been effective. Prioritizing underrepresented groups, such as Puerto Ricans, in future research will ensure trials are more representative, leading to better, more equitable healthcare outcomes.
Original language | American English |
---|---|
Pages | 43 |
State | Published - 13 Sep 2024 |
Event | 2024 Symposium on Tribal and Rural Innovations in Disparities and Equity for Health - Oklahoma State University College of Osteopathic Medicine at the Cherokee Nation, Tahlequah, United States Duration: 13 Sep 2024 → 13 Sep 2024 |
Conference
Conference | 2024 Symposium on Tribal and Rural Innovations in Disparities and Equity for Health |
---|---|
Abbreviated title | STRIDE 2024 |
Country/Territory | United States |
City | Tahlequah |
Period | 13/09/24 → 13/09/24 |